Expertise in
36
conditions

Dr. Mark R. Litzow

Hematology
MN - Cancer Hematology
200 1st St SW, 
Rochester, MN 
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
42 Years of Experience
Expertise in
36
conditions
MN - Cancer Hematology
200 1st St SW, 
Rochester, MN 

Overview

Mark Litzow is a Hematologist practicing medicine in Rochester, Minnesota. He has been practicing medicine for over 42 years.

Dr. Litzow is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Acute Lymphoblastic Leukemia (ALL), Bone Marrow Transplant, and Bone Graft.

He is actively involved in clinical research, co-authoring 551 peer reviewed articles and participating in 16 clinical trials. Dr. Litzow is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MN

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 6 Less Insurance Carriers -

Locations

MN - Cancer Hematology
200 1st St SW, Rochester, MN 55905

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Enrollment Status: Recruiting
Publish Date: September 03, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Samalizumab, BI-836858, Daunorubicin, Cytarabine, Azacitidine, AG-221, Entospletinib, Decitabine, Pevonedistat, AG-120, Gilteritinib, AZD5153, Venetoclax, TP-0903, AZD5991
Study Phase: Phase 2/Phase 3
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Biological, Drug, Procedure, Other
Study Drugs: Allopurinol, Cytarabine, Daunorubicin Hydrochloride, Vincristine Sulfate, Dexamethasone, Pegylated L-Asparaginase, Methotrexate, Cyclophosphamide, Mercaptopurine, Rituximab, Doxorubicin, Thioguanine, Inotuzumab
Study Phase: Phase 3
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Blinatumomab, Inotuzumab
Study Phase: Phase 2
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dasatinib, Dexamethasone, Doxorubicin Hydrochloride, Mesna, Methotrexate, Ponatinib Hydrochloride, Prednisone, Vincristine Sulfate
Study Phase: Phase 3
A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)
A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2026
Intervention Type: Other
Study Phase: Not Applicable
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
A Phase 2 Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients >/= 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Ph+ ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL (Newly Diagnosed or Relapsed/Refractory) With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Blinatumomab, Dasatinib, Mercaptopurine, Methotrexate, Methotrexate Sodium, Prednisone, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2026
Intervention Type: Drug, Other, Biological
Study Drugs: Dasatinib, Imatinib Mesylate, Nilotinib, Pembrolizumab
Study Phase: Phase 2
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
Enrollment Status: Completed
Publish Date: January 16, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Azacitidine, Cytarabine, Decitabine, Midostaurin, Nivolumab
Study Phase: Phase 2/Phase 3
A Multisite Phase Ib Study of Pevonedistat, Azacitidine (or Decitabine), and Venetoclax (PAVE) for the Treatment of Patients With Acute Myelogenous Leukemia (AML)
A Multisite Phase Ib Study of Pevonedistat, Azacitidine (or Decitabine), and Venetoclax (PAVE) for the Treatment of Patients With Acute Myelogenous Leukemia (AML)
Enrollment Status: Terminated
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Azacitidine, Venetoclax, Pevonedistat
Study Phase: Phase 1
View 7 Less Clinical Trials

551 Total Publications

Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents.
Older Age, STAG2, and DNMT3A Mutations Predict Superior Posttransplant Survival in Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents.
Journal: American journal of hematology
Published: July 11, 2026
Similar Doctors
Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

MN - Cancer Hematology

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-229-0068
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ayalew Tefferi is a Hematologist practicing medicine in Rochester, Minnesota. Dr. Tefferi is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Essential Thrombocythemia, Myeloproliferative Neoplasms (MPN), Splenectomy, and Bone Marrow Transplant. Dr. Tefferi is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

MN - Cancer Hematology

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-229-0068
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Angela Dispenzieri is a Hematologist practicing medicine in Rochester, Minnesota. Dr. Dispenzieri is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Primary Amyloidosis, POEMS Syndrome, Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Dispenzieri is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

MN - Cancer Hematology

200 1st St SW, 
Rochester, MN 
 (0.1 miles away)
507-229-0068
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Morie Gertz is a Hematologist practicing medicine in Rochester, Minnesota. Dr. Gertz is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Primary Amyloidosis, Multiple Myeloma, Waldenstrom Macroglobulinemia, Bone Marrow Transplant, and Tissue Biopsy. Dr. Gertz is currently accepting new patients.

Frequently Asked Questions about Dr. Mark R. Litzow

How do I make an appointment with Dr. Mark R. Litzow?

You can book an appointment with Dr. Mark R. Litzow by calling their office at 507-229-0068. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark R. Litzow a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark R. Litzow is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark R. Litzow specialize in?

While Dr. Mark R. Litzow is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Leukemia, and Acute Lymphoblastic Leukemia (ALL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Mark R. Litzow participate in research or clinical trials?

Yes. Dr. Mark R. Litzow has published 551 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Mark R. Litzow's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mark R. Litzow accept my insurance?

Dr. Mark R. Litzow accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 507-229-0068 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Litzow's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 8 Distinguished Conditions
View All 20 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile